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Abstract
Background: Expression microarrays have evolved into a powerful tool with great potential for
clinical application and therefore reliability of data is essential. RNA amplification is used when the
amount of starting material is scarce, as is frequently the case with clinical samples. Purification
steps are critical in RNA amplification and labelling protocols, and there is a lack of sufficient data
to validate and optimise the process.
Results: Here the purification steps involved in the protocol for indirect labelling of amplified RNA
are evaluated and the experimentally determined best method for each step with respect to yield,
purity, size distribution of the transcripts, and dye coupling is used to generate targets tested in
replicate hybridisations. DNase treatment of diluted total RNA samples followed by phenol
extraction is the optimal way to remove genomic DNA contamination. Purification of double-
stranded cDNA is best achieved by phenol extraction followed by isopropanol precipitation at
room temperature. Extraction with guanidinium-phenol and Lithium Chloride precipitation are the
optimal methods for purification of amplified RNA and labelled aRNA respectively.
Conclusion: This protocol provides targets that generate highly reproducible microarray data
with good representation of transcripts across the size spectrum and a coefficient of repeatability
significantly better than that reported previously.
Background
Expression microarrays have shown great potential for
clinical application [1,2], and therefore it is critical that
data is reproducible. Clinical specimens frequently con-
tain small amounts of RNA and amplification is required
to obtain sufficient material for expression analysis. RNA
amplification by T7-polymerase is commonly used to
generate cDNA or amplified RNA (aRNA) for direct and
indirect labelling reactions [3-6].
Nucleic acid purification and recovery steps have a critical
impact on the quality of the labelled targets for microarray
experiments. Although a variety of methods have been
applied for the purification steps [5-8], there has not been
a systematic evaluation to optimize these methods. We
present here a comprehensive study of all purification
steps involved in the process of indirect labeling of aRNA
(Figure 1), to generate anti-sense targets applicable on
both cDNA and oligonucleotide arrays [9].
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Effect of genomic DNA carry over on RNA amplification
To evaluate the optimal method for removal of genomic
DNA contamination from RNA samples, total RNA from
each of the five cell lines was treated using one of four
methods: Qiagen RNeasy minikit columns (with on-col-
umn DNase digestion); DNase treatment followed by 2.5
M LiCl precipitation, and DNase treatment (using two dif-
ferent RNA concentrations, D5 and D20) followed by PCI
extraction.
The efficiency of each method was first assessed by agar-
ose gel and Agilent Bioanalyzer. Agarose gel was sufficient
to demonstrate that specimens purified by the LiCl
method had a high level of genomic DNA contamination
(Figure 2A). Using the Agilent Bioanalyzer revealed that
both the column method and D20 samples had genomic
DNA carry over, manifested as a small shoulder after the
28S band (Figure 2B). To further evaluate the effect of
genomic DNA on downstream reactions, RNA samples
processed with each method were amplified and the prod-
ucts of amplification precipitated with LiCl to preserve
high molecular weight species. D5 samples generated
amplification products without heavy molecular weight
genomic bands, whereas the column method showed
genomic bands (Figure 2C). These findings were consist-
ent in the five cell lines studied. Contamination with
shorter genomic fragments could not be ruled out with
these methods.
Finally, to quantify the effect of genomic DNA contamina-
tion cDNA synthesis was conducted without the addition
of reverse transcriptase, but keeping all the downstream
steps for RNA amplification, including DNA polymerase.
In these circumstances cDNA synthesis cannot occur and
absorptions at 260 nm of the amplification products
reflect genomic DNA contamination and not aRNA. D5
samples showed minimal absorptions at 260 nm, whereas
other samples had significant amounts of nucleic acid
(Figure 2D). The experiments were also conducted with
the inclusion of reverse transcriptase as a control.
Application of DNase I (2 Units/1 µg of total RNA) to
diluted samples followed by phenol extraction is the most
effective method for removal of genomic DNA. Dilution
leads to easier access of DNase to genomic DNA and prob-
ably allows more efficient phenol extraction due to lower
viscosity of the sample. Genomic DNA contamination
could be a potential problem when quantifying the
amplification products and may interfere with the down-
stream reactions.
cDNA purification affects transcript representation
To evaluate the effect of cDNA clean up on amplified
products, total RNA samples from the five cell lines stud-
ied were processed with the optimized method (D5/PCI)
and 2 µg of total RNA from each cell line used for cDNA
synthesis. For cDNA purification 4 methods were tested:
column, PCI/ethanol at RT, PCI/ethanol at CT, and PCI/
isopropanol. Each purified sample was used for T7-ampli-
fication followed by recovery with 2.5 M LiCl precipita-
tion. PCI/isopropanol showed the highest overall yield
for both RNA samples of good quality (28S/18S atio of
Purification steps in indirect aRNA labellingFigure 1
Purification steps in indirect aRNA labelling. Methods 
evaluated are indicated for each step. Experimentally deter-
mined optimal methods are underlined. DNase – DNase I 
treatment; PCI – Phenol:Chloroform:Isoamyl alcohol; LiCl – 
Lithium Chloride; Ethanol at RT – ethanol at room tempera-
ture; Ethanol at CT – ethanol with cold incubation; LiCl-etha-
nol – Lithium Chloride/ethanol precipitation.Page 2 of 14
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Effect of genomic DNA contamination in total RNA. (A) 1% agarose gel of purified MCF-7 total RNA samples. L-1 kb 
ladder (Invitrogen); Col. – column purified RNA; D20 – DNase treated/PCI extracted (RNA concentration – 20 µg/100 µl); D5 
– DNase treated/PCI extracted (RNA concentration – 5 µg/100 µl); LiCl – DNase treated/Lithium Chloride purified. (B) Agi-
lent Bioanalyzer image of MCF-7 total RNA sample purified using column method. Arrow pointing at shoulder after 28S band 
indicating genomic DNA carry over. (C) 1% agarose/formamide denaturing gel of MCF-7 aRNA. L1 – 6000 RNA ladder 
(Ambion); L2-1 Kb ladder (Invitrogen). (D) Absorption at 260 nm of nucleic acid products derived from the 4 total RNA puri-
fication methods. 2 µg of total RNA from each of the five cell lines was amplified with and without reverse transcriptase being 
added to the cDNA synthesis reaction (with RT and no RT respectively). C – column; Li – LiCl precipitation; D5/D20 – as in A. 
Cell lines included MCF-7, ZR-75-1-1, OCUB-M, Cal51, and HCT-1187.Page 3 of 14
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Table 1). Column and PCI/ethanol at RT provided high
yields only for samples with 28S/18S ratio of 1.9.
To evaluate the effect of cDNA purification methods on
aRNA pattern, fluorescence absorptions were measured
using the Agilent Bioanalyzer at 100-nucleotide (nt),
1000 nt, and 6000 nt data points (representing short,
medium, and large size transcripts). For each total RNA
isolate, one amplification reaction was tested with each
cDNA purification method and fluorescence absorptions
for different methods were compared using the mean val-
ues obtained from the five cell lines (Figure 3A). The iso-
propanol method provided better recovery of both short
and large size transcripts. Ethanol at RT was less efficient
for small transcripts and the opposite was observed for
ethanol at CT. Columns resulted in lower recovery for
both small and large transcript sizes. Medium sized tran-
scripts were recovered with similar efficiency by all 4
methods. The difference in preserving smaller transcripts
was more evident for poor quality RNA samples (OCUB-
M with 28S/18S of 1.4) which showed significantly higher
fluorescence absorption at 100 nt with PCI/isopropanol
(Figure 3B) compared to PCI/ethanol at RT (Figure 3C).
The difference was less marked for other cell lines (data
not shown). The better overall yield and the ability to pre-
serve both long and short transcripts, suggests that PCI
extraction with isopropanol recovery is the method of
choice for cDNA purification.
Guanidinium-phenol extraction is the optimal method to 
purify aRNA
To evaluate aRNA purification methods, 3 µg of total RNA
from each cell line was amplified in twelve replicates
using the optimized total RNA and cDNA purification
methods described above. aRNA purification was then
performed in triplicate with each of the following 4 meth-
ods: column, LiCl, PCI, and guanidinium. Guanidinium
isothiocyanate (or guanidinium containing compounds
such as TRI reagent) was added to phenol extraction to test
whether the improved denaturing ability resulted in more
effective purification. Purified aRNA products were
assessed with respect to yield, purity (260/280 ratio), and
pattern of aRNA. The mean values obtained with different
methods for the five cell lines were compared (Figure 4A).
Columns had the lowest yield but showed optimal purity.
Both guanidinium and LiCl resulted in good yield and
purity. The yield was higher with PCI but aRNA purity was
suboptimal (1.7). These results show that phenol extrac-
tion alone could not efficiently purify aRNA probably due
to the high concentration of proteins such as spermidine
in the reaction buffer. The addition of guanidinium salt
with its chaotropic and denaturing effects [10], improved
the purification without compromising yield.
To evaluate the pattern of amplification, aRNA samples of
all five cell lines were analysed on both denaturing agar-
ose gels and the Agilent Bioanalyzer. Column-purified
samples showed a smear ranging from 400 to 6000 bp
(figure 4B), guanidinium purified samples showed a
smear from 100 to over 6000 nt (figure 4C), and samples
purified with LiCl had preservation of larger products
with a variable recovery of transcripts less than 200 bases
(data not shown). These data indicate that the guanidin-
ium method is optimal for aRNA purification.
The best method for aRNA recovery is dependent on total 
RNA quality
To evaluate the effect of total RNA quality on recovery of
aRNA, different amounts of total RNA (2, 3, and 5 µg)
from a cell line with poor quality RNA (OCUB-M: 28S/
18S = 1.4) and from a cell line with good quality RNA
(MCF-7: 28S/18S = 1.9) were tested. Amplification reac-
tions were performed in fifteen replicates for each starting
quantity of RNA from MCF-7 and OCUB-M. Five replicate
products from each starting quantity were precipitated
with either 2.5 M LiCl, column, or guanidinium methods
(figure 4D). The guanidinium method provided the best
aRNA recovery with OCUB-M (p #60; 0.01), showing that
samples with lower 28S/18S ratios can be reliably recov-
ered by this method. The yield of aRNA was significantly
higher with MCF-7 (p < 0.001) compared to OCUB-M.
Furthermore, LiCl and guanidinium methods provided
better yields in the MCF-7 samples compared to the
column method (p < 0.01). The LiCl was a robust method
Table 1: Yield of RNA amplification generated from different cDNA purification methods.*
Method 28S/18S = 1.9 28S/18S = 1.4
column 18 µg ± 2 7 µg ± 1
ethanol at RT 17 µg ± 2 10 µg ± 1
isopropanol 19 µg ± 3 14 µg ± 2
ethanol at CT 14 µg ± 2 12 µg ± 1
*RNA from MCF-7 and HCC-1187 (28S/18S = 1.9) and OCUB-M (28S/18S = 1.4) were used and reactions were repeated five times. Values 
represent averages with standard errors.Page 4 of 14
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OCUB-M samples.
RNA samples with low 28S/18S ratios have reduced
amplification efficiency and contain shorter transcripts.
Columns result in size exclusion of short aRNA products
and have therefore limited ability for recovery in lower
quality RNA samples. LiCl has a variable yield for short
transcripts and cannot efficiently precipitate RNA in low
concentrations (data not shown); therefore it is not relia-
ble for samples with low 28S/18S ratios. The guanidinium
method performs consistently for samples with different
qualities of starting RNA and is therefore the best method
for aRNA purification.
Analysis of aRNA generated after different cDNA purification methodsFigure 3
Analysis of aRNA generated after different cDNA purification methods. (A) Fluorescence absorptions at 100 nucle-
otides (100 nt), 1000 nucleotides (1000 nt), and 6000 nucleotides (6000 nt) data points. The results were obtained by plotting 
the mean fluorescence absorption values for the five cell lines using the different cDNA purification methods. cDNA purifica-
tion methods: Col. – Column; E-R – ethanol at room temperature; IS – Isopropanol; E-C – ethanol at cold temperature. (B) 
Pattern of amplified RNA from OCUB-M cell line using cDNA purified by isopropanol method. First peak-absorption at about 
100 nucleotides; second peak-absorption at 1000 nucleotides. (C) Pattern of amplified RNA from OCUB-M cell line using 
cDNA purified by ethanol at room temperature method.Page 5 of 14
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Analysis of aRNA purification. (A) Amplified RNA yields and 260/280 ratios with 4 methods of purification. Col – column; 
PCI – phenol/chlorform/isoamyl alchohol; LiCl – 2.5 M LiCl; G-P – guanidinium-phenol. (B) 1% denaturing agarose/formamide 
gel of MCF-7 aRNA purified using column (C) Agilent Bioanalyzer analysis of aRNA (from MCF-7) purified by G-P. 6000 nano 
marker from Ambion (blue) superimposed on the RNA trace. (D) Plot of aRNA yield in µg for different starting total RNA 
quantities. C1 – OCUB-M with Col.; L1 – OCUB-M with LiCl; G1 – OCUB-M with G-P; C2 – MCF-7 with Col.; L2 – MCF-7 
with LiCl; G2 – MCF-7 with G-P.Page 6 of 14
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labelling reaction
To study the effect of aRNA purity (260/280 ratio) on cou-
pling efficiency, labelling reactions of MCF-7 aRNA sam-
ples with 260/280 ratios from 1.5 to 2 were performed
(Figure 5A). Cy5 labelling was done in triplicate for each
different ratio using 10 µg of aRNA and purified by LiCl
precipitation. Coupling efficiency was measured using the
Agilent Bioanalyzer by obtaining mean ratios of coupled
to total Cy5 fluorescence readings. The 320/650 ratio
(Cy5) was also determined using the Nanodrop device.
The results showed a positive correlation between aRNA
purity and coupling efficiency (Figure 5A). Samples with
260/280 of less than 1.8 had coupling ratios below 0.5
(Figure 5B), but with the increase of 260/280 to above 1.8
coupling efficiency improved to over 0.9 (Figure 5C). Fur-
thermore, Cy5-labelled products with 320/650 ratios over
0.1 (Figure 5D) showed a lower coupling efficiency (p <
0.01) compared to products with ratios equal or less than
0.1 (Figure 5E). The experiments were also performed
with Cal51 aRNA samples with similar results (data not
shown).
These data demonstrate that purification of aRNA is criti-
cal for obtaining an efficient labelling reaction. The pres-
ence of protein impurities measured by a 260/280 < 1.8
inhibits dye coupling most likely by competing with ami-
noallyl groups for esterification with Cy dyes. Measure-
ment at 320 nm indicates background absorption and in
the past 320/260 ratios have been used to assess the purity
of nucleic acids [11]. Measurements at 650 and 550 nm
are for Cy5 and Cy3 dyes respectively [12,13]. We applied
320/650 and 320/550 ratios to estimate the insoluble by-
products for Cy5 and Cy3 coupling reactions, which serve
as measures for the purity of labelled products.
A correlation coefficient of 0.95 (n = 14) between 320/
550 and 320/650 ratios was noted in each sample set sug-
gesting that 320/550 ratios can be used to assess Cy3
coupling reactions. Background at 320 nm may represent
dye particles or other insoluble by-products of the cou-
pling reaction and at times these particles can also be seen
on Agilent Bioanalyzer as a slow moving peak (data not
shown). Since 320/550 and 320/650 values can be easily
measured using a spectrophotometer device, they provide
a fast and cost effective method for evaluating the quality
of labelled aRNA products.
LiCl is the optimal method for purification of labelled 
aRNA
The recovery rates and free-dye removal of labelled aRNA
were evaluated by four different purification methods
(column, LiCl-ethanol, PCI, and LiCl) using 10 µg of gua-
nidinium-purified aRNA from MCF-7 cell line. Since LiCl
is not an effective precipitant for low concentrations of
RNA, it is important not to dilute the samples at this stage
(we use 10 µg of starting aRNA and apply 2.5 M final LiCl
concentration from 7.5 M LiCl working stock). For each
purification method five replicates of Cy3 and Cy5 label-
ling were tested. The ratios of recovered labelled aRNA to
starting aRNA were measured. Mean recovery ratios for
combined Cy3 and Cy5-labelled aRNAs were compared
and coupling efficiency of Cy5 (see above) determined as
an indicator for free-dye removal using Agilent Bioana-
lyzer (Figure 5F). LiCl had the best overall performance
with a recovery rate of 0.6 and coupling efficiency of 0.95.
Optimised purification protocol generates reproducible 
expression data
To evaluate hybridisation efficiency, labelled-aRNA tar-
gets from Cal51 and ZR-75-1-1 cell lines were generated
using the experimentally determined optimal purification
steps (underlined in Figure 1). For each cell line RNA
sample two separate amplification reactions were carried
out independently using the optimised method. After
labelling of each amplified RNA with Cy3 and Cy5, the
reactions were purified with the LiCl method and used in
hybridisation experiments. With a total of four slides, a
balanced dye-reversal experiment was carried out by
hybridising Cy5-labelled targets from each cell line
against Cy3-labelled targets of the other cell line using one
set of amplified products for each two slides. This gener-
ated a total of two technical replicate slides (same dye
order) and two dye-reversals slides (opposite dye order).
Since each slide contained an internal replicate, the data
generated after hybridisation included a total of four
internal replicates, eight technical replicates, and sixteen
dye-reversal combinations. Data were normalised using
the SMA package and analysed using R program (Figure
6). Correlation coefficients in figure 6 represent each pair
of replicate and dye-reversal data set with mean values of
0.85 (± 0.05, n = 4) for internal replicates, 0.8 (± 0.01, n
= 8) for technical replicates, and 0.63 (± 0.02, n = 16) for
dye reversal pairs. The average A value (median of log2
intensities for two dye channels) across slides was 8.7 and
85% of the spots (an average of 11,500/13,000 per each
slide) had measurable signals. These data suggest that the
optimised method described here can generate reproduc-
ible microarray results with good signal intensities and
provide hybridisation for the majority of spotted cDNA
probes indicating a diverse range of transcript
representation.
Transcript representation and repeatability
Two housekeeping genes with extreme size distributions
were selected to test their representation in aRNA by RT-
PCR: as an example of a small transcript the R38b sno
gene with a cDNA size of only 86 bases and as an example
of long transcript human guanine nucleotide exchange
factor p532 gene with a cDNA size of 15,164 bases. ThePage 7 of 14
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Effect of aRNA purity and labelled-aRNA purification. (A) Graph showing coupling efficiency (C) and 320/650 (B) val-
ues for six MCF-7 aRNA samples with different 260/280 ratios. (B) Agilent Bioanalyzer pattern of MCF-7 Cy5-labelled target 
using an aRNA with 260/280 ratio of 1.6. Sharp spikes represent uncoupled Cy5 dye. (C) Same as B for aRNA with 260/280 
ratio of 2 and coupling efficiency near 1. (D) NanoDrop® ND-1000 Spectrophotometer absorptions at 320 and 650 nm wave-
lengths of a MCF-7 Cy5-labelled target. 320/650 ratio-0.6. (E) Same as in d (different sample). 320/650 ratio-0.09. (F) Recov-
ery rates (R) and coupling efficiencies (C) for different labelled-aRNA purification methods. Data is presented for MCF-7 cell 
line and measurements represent an average of three separate reactions. Li-ETOH – LiCl-ethanol; PCI – phenol/chloroform/
isoamyl alcohol.Page 8 of 14
(page number not for citation purposes)
BMC Genomics 2004, 5 http://www.biomedcentral.com/1471-2164/5/9presence of both transcripts in aRNA was confirmed (Fig-
ure 7A,7B). Total RNA was also tested to confirm that the
transcripts were present (data not shown). PCR reactions
with no cDNA were used as negative controls in all
experiments.
The size representation of the transcripts was also tested
globally using the array data. The A value (median of log2
intensity) was categorized for long transcripts >7000 nt (n
= 239), short transcripts <500 nt (n = 38), and medium
transcripts 500–7,000 nt (n= 5,375). The three size
Scatter plots and correlation coefficients for each microarray experiment pairFigure 6
Scatter plots and correlation coefficients for each microarray experiment pair. Cal51 versus ZR-75-1-1 cell lines. 
Rep1 and Rep2 represent the replicates within each slide (internal replicates). Slides d94/d97 and d96/d98, have the same dye 
orders. Slides d94/d97 are dye reversal experiments for slides d96/d98.Page 9 of 14
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representation independent of the size (Figure 7C). It
should be noted that the amplified products were hybrid-
ized without fragmentation and that longer transcripts
could potentially mark the corresponding features with
more label than shorter transcripts, which can lead to an
overestimation of A values for the longer transcripts.
To further evaluate the quality of the microarray data, the
coefficient of repeatability (CR) was determined as
described by Jenssen et al [14]. Repeatability of M values
across the eight replicates showed a median of 0.16 for all
three size categories (Figure 7D). These results are signifi-
cantly better when compared with published CR values of
five landmark microarray studies ranging from 0.518 to
1.101 [see ref. [14]]. Although the presented method was
not directly compared to the other purification techniques
in terms of reproducibility and repeatability, the better CR
values compared to the published studies in addition to
the improved transcript representation and dye coupling
support the contention that the protocol described here is
an improvement over currently used methods.
A major concern during the purification steps is the exclu-
sion of transcripts based on their size, which can poten-
tially lead to selection bias in subsequent expression
microarray analysis. RT-PCR in addition to analysis of A
and CR values demonstrated good representation for var-
ious size transcripts using the purification protocol
described here.
Representation of small and large transcripts in aRNA generated by optimised purification protocolFigure 7
Representation of small and large transcripts in aRNA generated by optimised purification protocol. (A) 2.5% 
agarose gel of R38b RT-PCR product using HCC-1187 aRNA as template. (B) 0.7% agarose gel of p532 RT-PCR product using 
HCC-1187 aRNA as template. (C) Box-plot for A values (average log2 intensity) of three transcript size categories (Long: > 
7,000 bases, Medium: 500–7,000 bases, Short: <500 bases). (D) Coefficients of repeatability (CR) as described by Jenssen et al 
[14], are demonstrated in 8 replicate data sets for three transcript size categories.Page 10 of 14
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This manuscript describes a rigorous evaluation of purifi-
cation methods involved in RNA amplification and
labelling. The proposed purification protocol (see Figure
1, underlined methods) provides good yield, purity,
coupling efficiency and preservation of different size
transcripts. It is also cost effective when compared with
methods using multiple column steps, and provides
labelled targets for microarray hybridisation with an opti-
mal coefficient of repeatability.
Methods
Samples and total RNA extraction
Total RNA was isolated from five breast cancer cell lines
(MCF-7, HCC-1187, Cal51, ZR-75-1-1, and OCUB-M)
using TRI-reagent (Sigma) following the manufacturer's
recommendations.
Purification of total RNA and genomic DNA removal
The following were tested:
Column method, using RNeasy mini-kit (Qiagen) with on-
column DNase I treatment, following the manufacturer's
instructions.
Non-column methods, using DNase I treatment followed by
a clean-up step. For DNase treatment 2 units of DNase I
(Roche Applied Sciences) were used per µg of total RNA at
37°C for 30 minutes. The reaction was tested on total
RNA dilutions of 20 µg/100 µl and 5 µg/µl (D20 and D5
respectively). Two clean-up methods were evaluated:
1- Lithium Chloride (LiCl) precipitation. D20 samples
were purified using a final concentration of 2.5 M LiCl.
After incubation at -20°C for 2 hours the sample was cen-
trifuged (16,000 g) at 4°C for 20 minutes (min). The pel-
let was then washed with 70% ethanol before drying.
2- Extraction with phenol:chloroform:isoamyl alcohol
(25:24:1, pH: 5.2, PCI). D20 and D5 samples were mixed
with one volume of PCI in a Phase-Lock-Gel™ (PLG) tube
(Heavy Gel, Eppendorf). After mixing, the tube was centri-
fuged at room temperature (RT) for 5 min. The aqueous
phase was transferred to a new PLG tube and a second
extraction was done using chloroform. The aqueous phase
was mixed with 100% ethanol and 0.1 volumes of 7.5 M
NH4Acetate, incubated at -20°C from 2 hours to over-
night (ON), followed by washing with 70% ethanol.
RNA amplification
cDNA synthesis
First strand cDNA was synthesized using 1 to 5 µg of total
RNA (see below). RNA was mixed with 1 µl of T7-oligo
(dT) primer (100 ng/µl, Ambion) in nuclease-free water to
a total volume of 8 µl and added to EndoFree RT™ enzyme
(Ambion) in a 21 µl reaction following the instruction
manual. The reaction was incubated at 50°C for 2 hours.
Second strand cDNA was synthesized by mixing the first
strand reaction with 95 µl nuclease-free water, 15 µl KOD
XL Buffer (Novagen®), 15 µl of dNTPs (final concentration
0.2 mM), 1 µl RNase H (10 U/µl, Ambion), and 3 µl of
KOD XL polymerase (Novagen®). Incubation was at 37°C
for 5 min, followed by 94°C for 2 min, 65°C for 1 min
and 75°C for 30 min. The reaction was stopped by 15 µl
of 0.1 M NaOH/2 mM EDTA and incubated at 65°C for
10 min and neutralized by 15 µl of 0.1 M HCl.
Reactions carried out without reverse transcriptase were
used as negative controls.
Purification of cDNA
cDNA was purified using the following methods:
1) cDNA clean-up column (DNA clear™ kit, Ambion) using
the manufacturer's instructions.
2) PCI (pH:8.2) extraction with isopropanol precipitation at
room temperature (Isopropanol method): reaction volume
was adjusted to 200 µl with nuclease-free water, mixed
with 200 µl of PCI and transferred to a PLG tube. After
centrifugation (12,000 g) at RT for 5 min, the aqueous
phase was transferred to a fresh PLG tube and a separate
chloroform extraction was carried out. The final aqueous
phase was precipitated using 1 µl of linear acrylamide (0.1
µg/µl, Ambion), 0.5 volumes of 7.5 M NH4Acetate and
two volumes of isopropanol. The mixture was incubated
at RT for 10 min and centrifuged (12,000 g) at RT for 20
min. The pellet was washed with 500 µl of 75% ethanol,
centrifuged for 5 min, dried, and re-suspended in nuclease
free water.
3) PCI extraction with ethanol precipitation at room tempera-
ture (ethanol at RT): Ethanol was replaced for isopropanol
after PCI extraction and sample was immediately centri-
fuged (Modified from Zhao et al, [8]).
4) PCI extraction with cold ethanol precipitation (ethanol at
CT): After PCI extraction, 0.1 volumes of 7.5 M
NH4Acetate were added to the aqueous phase and mixed
with 2.5 volumes of pre-chilled 100% ethanol. The mix-
ture was incubated at -20°C for 2 hours and centrifuged at
4°C for 20 min, followed by washing with pre-chilled
70% ethanol and re-suspension.
In vitro transcription to generate amplified RNA
aRNA was generated by T7 MEGAscript™ kit (Ambion)
with incorporation of aminoallyl-UTP (aa-UTP) in the
process. 15 µl of purified cDNA was mixed with 3 µl of
aaUTP solution (50 mM, Ambion), 12 µl of ATP, CTP,Page 11 of 14
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T7 10 × reaction buffer and 4 µl of T7 enzyme mix. A ratio
of 1:1 for aaUTP: UTP was used [9]. The reaction mix was
incubated at 37°C for 14 hours followed by treatment
with 2 µl of DNase I (2 U/µl) at 37°C for 30 minutes.
Purification of amplified RNA
The following methods were used to purify aRNA:
1) Column purification with RNeasy kit (Qiagen) following
the manufacturer's instruction.
2) PCI extraction (pH: 5.2): an equal volume of PCI was
added to aRNA and transferred to the PLG tube as
described above. After two rounds of PCI extraction, a
separate chloroform extraction step was carried out fol-
lowed by precipitation with NH4Acetate and ethanol at -
20°C.
3) LiCl precipitation: aRNA was precipitated with a final
concentration of 2.5 M LiCl. After cold incubation at -
20°C for 2 hours, the sample was precipitated and washed
as described above.
4) Guanidinium Isothiocyanate-phenol or TRI-reagent™ purifi-
cation (guanidinium method). After addition of 100 µl of
4 M guanidinium isothiocyanate to the aRNA sample, it
was purified using the PLG tubes and phenol as described
by the manufacturer (PLG manual). Alternatively 1 ml of
TRI-reagent™ (Sigma) was added to each aRNA sample,
mixed well and transferred to a PLG tube. After adding
200 µl of chloroform, the solution was mixed by shaking,
incubated at RT for 2 min and centrifuged (12,000 g) at
4°C for 20 min. The aqueous phase was then transferred
to a new PLG tube and mixed with 600 µl of chloroform.
After centrifuging (12,000 g) at 4°C for 10 min, the aque-
ous phase was transferred to a 1.5 ml tube and precipi-
tated by adding 1 µl of linear acrylamide (0.1 µg/µl,
Ambion), 0.1 volumes of 3 M NaAcetate and an equal vol-
ume of isopropanol followed by incubation at -20°C ON.
The centrifuge and washing steps were carried out as
described previously for PCI extraction.
Labelling of amplified RNA
Coupling reaction
Aminoallyl modified-aRNA (aa-aRNA) was coupled with
monoreactive Cy3 and Cy5 dyes (Amersham). One vial of
dye was dissolved in 40 µl of dimethylsulfoxide (DMSO)
and divided into aliquots of 4 µl and dried by speed vac-
uum. To 10 µg of aa-aRNA in 6.7 µl of nuclease-free water,
10 µl of DMSO, and 3.3 µl of 0.3 M NaHCO3 (pH: 9)
were added. The mixture was immediately transferred to
Cy3 or Cy5 dried dyes and mixed by pipetting. Coupling
reactions were carried out for 1 hour in the dark followed
by quenching with 4.5 µl of 4 M hydroxylamine for 15
minutes.
Purification of labelled aRNA
Labelled targets were cleaned-up by the following
methods:
1) Column purification with Qiagen RNA columns.
2) LiCl-Ethanol precipitation was carried out by adding 0.1
volumes of 4 M LiCl and 2.5 volumes of pre-chilled 100%
ethanol. The mix was incubated at -20°C for 2 hours and
centrifuged (12,000 g) at 4°C for 20 min followed by
washing with 500 µl of pre-chilled 70% ethanol and re-
spinning at 12,000 g for 5 min. The pellet was then air-
dried and re-suspended in nuclease-free water.
3) PCI extraction (pH: 5.2): One round of PCI extraction
followed by precipitation.
4) LiCl precipitation. To each reaction 12.5 µl of 7.5 M LiCl
was added (2.5 M final concentration). The mixture was
incubated at -20°C overnight followed by precipitation as
described before.
Assessment of RNA quality
The NanoDrop® ND-1000 Spectrophotometer (Nano-
Drop Technologies) was used to determine: 260/280
ratio, to assess total RNA and aRNA purity; 320/550 and
320/650 ratios, to evaluate Cy3 and Cy5-labelled aRNAs
respectively.
Quality of total RNA and patterns of amplified or labelled
aRNA were evaluated using the Agilent-2100 Bioanalyzer
with the RNA 6000 Nano Lapchip® kit (Agilent Technolo-
gies) and also by 1% denaturing agarose/formamide gels.
Coupling efficiency for Cy5 dyes was assessed using the
Agilent Bioanalyzer.
Hybridisation of cDNA microarrays
Expression microarrays containing 6528 pairs of duplicate
cDNA spots were used (Cancer Research UK DNA Micro-
array Facility at the Institute of Cancer Research; CR-UK
DMF Human 6.5 k genome-wide array).
Labelled targets from two cell lines, Cal51 and ZR-75-1-1,
were generated using the optimized purification protocol.
A total of 4 hybridizations were done: two slides were
used with the same dye combination (replicates) and two
slides with reversal of the dyes (dye reversal).
For each hybridization 2 µg of each Cy3 and Cy5-labelled
targets (corresponding to 110–130 pmols of dye) were
used. Hybridisation was performed as described http://
www.crcdmf.icr.ac.uk with minor modifications. In brief,Page 12 of 14
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to which 15 µl of pre-warmed (37°C) Amersham Hybrid-
isation Buffer (Amersham Biosciences), 30 µl of deionised
formamide, and 1 µl of Poly-dA (10 µg/µl, Amersham
Biosciences) were added. After mixing, the samples were
denatured at 92°C for 2 min and centrifuged at 12,000 g
for 5 min. Slides were placed in Glass Array Hybridisation
Cassettes (Ambion), targets were applied and cover slips
fitted. Hybridization was carried out at 42°C overnight in
a waterbath.
Washing was done in 2XSSC, 0.2%SDS at 42°C for 30
min, 2XSSC, 0.1%SDS at 42°C for 30 min, and 0.1XSSC,
0.1%SDS at RT for 10 min. Slides were then plunged ten
times in 0.1XSSC to remove extra SDS with subsequent
washes in 0.1XSSC two times for 2 minutes and once for
one minute. Subsequently they were washed in 0.01XSCC
for 15 seconds and submerged quickly in 96% ethanol
followed by spin-drying at 500 rpm for 5 min.
Scanning, feature extraction and analysis
Slides were scanned using the ScanArray® 4000 microarray
analysis system (Packard BioChip Technologies). Feature
extraction was done using ScanArray Express software
(Packard BioChip Technologies) and spots with high
background were flagged manually. Data was transferred
as tab delimited text files and analyzed using R mathemat-
ical program http://cran.us.r-project.org and Statistics for
Microarray Analysis package (SMA), http://stat-www.ber
keley.edu/users/terry/zarray/Software/smacode.html. Stu-
dent's t-test and Chi-Square statistics were used for analy-
sis of parametric and non-parametric factors respectively.
Bioinformatics
The longest annotated transcript for each of the analysed
genes was computationally determined after combining
the information available in RefSeq [http://
www.ncbi.nlm.nih.gov/RefSeq/ and http://
ncbi.nlm.nih.gov/books/bookres.fcgi/handbook/
ch18d1.pdf, The NCBI handbook, Chapter 18. The Refer-
ence Sequence (RefSeq) Project] and Ensembl (Human
v.16.33.1, http://www.ensembl.org) databases [15]. The
search was automated by using BioPerl http://www.biop
erl.org and Ensembl Perl modules on a Linux platform
[16].
Reverse Transcription-PCR of selected transcripts
RT-PCR was done using RNA from cell line HCC-1187 to
amplify a 50 base pair (bp) fragment of R38bsno and a
7130 bp fragment of Human guanine nucleotide exchange
factor (p532) located 1 kb from the 3' end of the cDNA.
Reverse transcription was done using either 5 µg of total
RNA with 1 µl of oligo-dT (16) primer (Roche Applied
Biosciences) or 2 µg of aRNA with 25 pmols of gene spe-
cific reverse primer. The volume was adjusted to 9 µl with
nuclease-free water, incubated at 70°C for 3 min and
cooled on ice for 2 min. The following were added to the
primed RNA: 4 µl of first strand buffer (BD Biosciences
Clontech), 2 µl of 0.1 M DTT, 1 µl of RNase Inhibitor, 2
µl of 10 mM dNTPs, and 2 µl Powerscript Reverse™ Tran-
scriptase (BD Biosciences Clontech). The reaction was
incubated at 42°C for 2 hours, heat inactivated for 15 min
at 70°C, and treated with 1 µl of Ribonuclease H
(Promega) at 37°C for 30 min.
The primers used for PCR amplification were (p532 prim-
ers designed as described [17]):
R38bForward-5'GCTGAGTCCATGATGATTTC3'
R38bReverse-5'GCCTTTCTTTGCCTTCAGAC3'
p532Forward-5'AACTCACGGCAGTGGAGGGAAAG3'
p532Reverse-5'TGCTGTTCTGGTTGTTGGGGCTA3'
PCR conditions were:
For R38b-2 µl of reverse transcription product, 8 µl of
MgCl2 (25 mM), 4 µl of 10 × PCR Buffer2 (Promega), 2
µl of 10 mM dNTPs, 1 pmol of each of the primers, and 1
µl of AmpliTaq polymerase (Promega). The volume was
adjusted to 50 µl and thermal cycling carried out for 1 min
at 95°C, 45 seconds at 51°C, 1 min at 72°C for 30 cycles
with a 10 min extension period at 72°C in the last cycle.
As a negative control, cDNA was excluded from the PCR
reaction. The product was analysed on a 2.5% agarose gel.
For p532-2 µl of reverse transcription product, 2 µl of each
of the primers (5 pmol/µl), and KOD XL Polymerase
(Novagen®) following the product instructions. Thermal
cycling was carried out for 10 seconds at 94°C and 7.1
minutes at 68°C for 35 cycles, followed by 10 minutes at
72°C. Negative control included a PCR reaction without
cDNA. The PCR product was analysed on a 0.7% agarose
gel.
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